Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors. In an interview with CURE®, Dr. Eric K.

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...

These tumors can arise de novo or can be associated with other myeloid disorders -- acute myeloid leukemia (AML) or CML, myeloproliferative, or myelodysplastic conditions. Presentation can occur ...

Kineta is leveraging its deep expertise in innate immunity, and particularly myeloid cells, to develop innovative, first-in-class therapies with a primary focus on cancer. To date, immune-based ...

The FDA has approved Bristol Myers Squibb’s (BMS) Opvido Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous (SC) administration in most adult solid tumor indications previously approved for ...

which can comprise up to 25 percent of the tumor’s mass. Myeloid cells invade tumors in response to diverse inflammatory stimuli produced by the tumor. Invading myeloid cells differentiate into ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo ...